Want to see GRDN full AI Analyst Report?
GRDN Stock Chart & Stats
$37.48
$1.01(2.50%)
At close: 4:00 PM EDT
$37.48
$1.01(2.50%)
Day’s Range― - ―
52-Week Range$23.14 - $48.33
Previous Close$41.46
Volume315.81K
Average Volume (3M)597.80K
Market Cap
$2.59B
Enterprise Value$2.63K
Total Cash (Recent Filing)$89.81M
Total Debt (Recent Filing)$35.24M
Price to Earnings (P/E)40.4
Beta0.52
Next Earnings
Nov 17, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.05
Shares Outstanding49,798,904
10 Day Avg. Volume808,281
30 Day Avg. Volume597,796
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)9.12
Price to Sales (P/S)1.30
P/FCF Ratio23.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$49.80Price Target Upside32.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.3
Revenue Forecast (FY)$1.44B
Bulls Say, Bears Say
Bulls Say
Growth And GuidanceRaised full-year guidance, combined with 23% first-half adjusted EBITDA growth, indicates that execution is outpacing prior expectations. Sustained operating progress can strengthen internal funding capacity, support expansion, and improve the durability of earnings growth over the next several quarters.
Balance Sheet StrengthVery low leverage and a larger cash balance materially improve financial flexibility. A healthier capital base allows Guardian to fund acquisitions and greenfield investments while reducing exposure to refinancing pressure, making the business better positioned to absorb industry volatility and pursue growth.
Expansion And Service ScaleThe company is extending its long-term-care pharmacy footprint through acquisitions and organic openings while serving a substantial resident base. This combination can deepen local market presence, broaden operating scale, and create a platform for recurring growth as new locations mature.
Bears Say
IRA Reimbursement HeadwindsIRA-related pricing reductions are creating a structural gap between underlying demand and reported revenue growth. Continued reimbursement pressure, including future drug tranches, could restrain top-line expansion and make reported results less reflective of operational activity over the coming periods.
Ramp-Related Margin DilutionNew locations and acquired operations remain below the corporate margin profile while they ramp, weighing on consolidated profitability. Although dilution improved from the prior quarter, continued expansion may temporarily limit margin gains and require sustained execution before the investments reach mature economics.
Profitability And Cash Conversion VolatilityThe rebound to profitability is encouraging, but the recent history shows that earnings have not yet demonstrated consistent performance across cycles. Operating cash flow below net income also points to timing or working-capital effects that may make cash generation less predictable and constrain planning.
Guardian Pharmacy Services, Inc. Class A News
GRDN FAQ
What was Guardian Pharmacy Services, Inc. Class A’s price range in the past 12 months?
Guardian Pharmacy Services, Inc. Class A lowest stock price was $23.14 and its highest was $48.33 in the past 12 months.
What is Guardian Pharmacy Services, Inc. Class A’s market cap?
Guardian Pharmacy Services, Inc. Class A’s market cap is $2.59B.
When is Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date?
Guardian Pharmacy Services, Inc. Class A’s upcoming earnings report date is Nov 17, 2026 which is in 45 days.
How were Guardian Pharmacy Services, Inc. Class A’s earnings last quarter?
Guardian Pharmacy Services, Inc. Class A released its earnings results on Aug 06, 2026. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.262 by $0.028.
Is Guardian Pharmacy Services, Inc. Class A overvalued?
According to Wall Street analysts Guardian Pharmacy Services, Inc. Class A’s price is currently Undervalued.
Does Guardian Pharmacy Services, Inc. Class A pay dividends?
Guardian Pharmacy Services, Inc. Class A does not currently pay dividends.
What is Guardian Pharmacy Services, Inc. Class A’s EPS estimate?
Guardian Pharmacy Services, Inc. Class A’s EPS estimate is 0.31.
How many shares outstanding does Guardian Pharmacy Services, Inc. Class A have?
Guardian Pharmacy Services, Inc. Class A has 49,798,904 shares outstanding.
What happened to Guardian Pharmacy Services, Inc. Class A’s price movement after its last earnings report?
Guardian Pharmacy Services, Inc. Class A reported an EPS of $0.29 in its last earnings report, beating expectations of $0.262. Following the earnings report the stock price went up 11.046%.
Which hedge fund is a major shareholder of Guardian Pharmacy Services, Inc. Class A?
Currently, no hedge funds are holding shares in GRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Guardian Pharmacy Services, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.80 (32.87% Upside)
$49.80 (32.87% Upside)
Blogger Sentiment
Bullish
GRDN Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 80.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Guardian Pharmacy Services, Inc. Class A
Guardian Pharmacy Services, Inc. operates as a pharmaceutical service provider, delivering an extensive array of tech-driven solutions. These services are specifically crafted to enhance the care of residents within long-term health care facilities (LTCFs) across the United States. The company specializes in offering personalized clinical assistance, efficient drug distribution, and comprehensive administrative support. These provisions are particularly beneficial for individuals in less acute long-term care environments, such as assisted living communities, behavioral health centers, and group homes. To bolster its operations, the company offers Guardian Compass, a platform that generates insightful dashboards from its extensive data warehouse. This tool enables its network of local pharmacies to effectively strategize, monitor performance, and refine their business processes. Furthermore, Guardian Pharmacy Services develops dedicated GuardianShield Programs for LTCFs. The company was established in 2003 and is based in Atlanta, Georgia.
GRDN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a positive operational and financial trajectory: strong adjusted EBITDA growth (23% YTD; 19% Q/Q), improved gross profit (+18% YoY), raised full-year guidance, robust clinical impact and disciplined capital allocation with nearly $90M cash and active M&A/greenfield expansion. Offsetting these positives are clear reimbursement headwinds from IRA pricing reductions that materially depressed reported revenue (Q2 +2%) and are expected to cause low single-digit reported declines in H2, continued margin dilution from ramping acquisitions/greenfields (though improving), and some cost pressures (fuel). Management emphasized mitigation actions, internal succession and disciplined deployment of capital, leaving the outlook upgraded but with ongoing uncertainty tied to future IRA tranches and integration ramps.View all GRDN earnings summariesGRDN Stock 12 Month Forecast
Average Price Target
$49.80
▲(32.87% Upside)